Quantcast
Last updated on April 19, 2014 at 1:20 EDT

Latest Thrombosis Stories

2012-11-12 11:57:13

For years, researchers have known that antiphospholipid antibodies (aPLs) can cause pregnancy loss and clotting, but they haven't known the true scope of the problem. Now a new study provides the first estimates of the prevalence of these antibodies in patients suffering from pregnancy loss, stroke, myocardial infarction, and deep vein thrombosis. "Based on the available data, our best estimate is that around 10 to 15% of clotting disorders are associated with autoimmune antiphospholipid...

2012-11-07 16:26:39

LOS ANGELES, Nov. 7, 2012 /PRNewswire/ -- Twelve-month data from the Global Anticoagulant Registry in the FIELD (GARFIELD) show that poor management of stroke prevention therapy is widespread in everyday clinical practice, which may lead to elevated rates of mortality, stroke and bleeding among individuals with newly diagnosed with atrial fibrillation (AF). Data from the GARFIELD Registry describes AF management and outcomes in everyday clinical practice, highlighting unmet...

2012-10-25 07:30:51

TOKYO, Oct. 25, 2012 /PRNewswire/ -- Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that it has completed patient enrolment in the global Hokusai-VTE phase 3 study investigating the once-daily oral factor Xa inhibitor edoxaban for the treatment and prevention of recurrence of venous thromboembolism (VTE) in patients who have had an acute symptomatic deep vein thrombosis (DVT), pulmonary embolism (PE), or both.(1,2 ) Hokusai-VTE is the largest single phase 3...

2012-10-25 04:00:15

U.S. Federal District Judge Rodney W. Sippel, Who is Overseeing Hundreds of NuvaRing Injury Lawsuits, Has Announced that the First Trial in the NuvaRing Litigation Will Begin on May 6, 2013. Melville, NY (PRWEB) October 24, 2012 The NuvaRing birth defect lawyers at Alonso Krangle LLP, a national law firm focused on fighting for the rights of serious personal injury victims, report that the federal litigation established for NuvaRing side effect lawsuits is moving forward. U.S. District...

2012-10-22 22:42:10

Fainting after recent air travel could be a sign of pulmonary embolism (PE), a potentially fatal blockage in the lungs. Syncope or fainting is an uncommon symptom of pulmonary embolism; however, new research presented at CHEST 2012, the annual meeting of the American College of Chest Physicians (ACCP), found that fainting associated with recent air travel may be a key indicator for PE diagnosis. Fainting as a precursor to PE diagnosis was also associated with a saddle embolism, a larger and...

2012-10-22 04:01:45

NuvaRing Lawsuit Alleges Merck and Other Defendants Failed to Properly Disclose the Known Safety Hazards Associated with NuvaRing, Including an Increased Risk of Pulmonary Embolism. Vandalia, Ohio (PRWEB) October 21, 2012 The national law firm of Wright & Schulte LLC has filed a NuvaRing pulmonary embolism lawsuit on behalf of an El Paso, Texas, woman who suffered a pulmonary embolism less than a year after she began using the NuvaRing birth control device. The Nuvaring side effect...

2012-10-16 11:03:20

Johns Hopkins researchers find computerized checklist better at finding best preventive strategy A computerized checklist system designed to help physicians identify and use the best methods of preventing potentially deadly blood clots in hospitalized trauma patients dramatically reduced the number of these dangerous venous thromboembolisms (VTEs), new Johns Hopkins research suggests. When a doctor enters medical orders for such patients, the automated checklist recommends...

2012-10-13 07:21:14

BOSTON, Oct. 13, 2012 /PRNewswire/ -- The pros and cons of newer versus older antiplatelet agents in patients with diabetes, the utility of genetic and platelet function testing, and the value of triple combination antiplatelet therapy will be debated by experts at a perennial favorite Cardiometabolic Health Congress (CMHC) session today. The "Hot Topics in Thrombosis and ACS" session is moderated by Deepak L. Bhatt, MD, MPH, professor of medicine at Harvard Medical School, chief of...

2012-10-03 22:20:52

ADDISON, Ill., Oct. 4, 2012 /PRNewswire/ -- ArjoHuntleigh announced today that it has been awarded a three-year contract with Premier Purchasing Partners, L.P., the group purchasing unit of the Premier healthcare alliance, for its vascular compression therapy systems. The agreement, effective December 1, 2012, allows Premier members, at their discretion, to take advantage of special pricing and terms pre-negotiated by Premier for ArjoHuntleigh's range of Flowtron® vascular...

2012-10-02 02:30:04

CAMBRIDGE, Mass., Oct. 2, 2012 /PRNewswire/ -- Thrombolytic Science International (TSI) today announced the initiation of a Phase 1 study of TS01, a new-generation clot-dissolving therapy intended for the treatment of acute ischemic stroke. This first-in-man randomized, double-blind, placebo-controlled study will assess the overall safety and tolerability of TS01 in healthy adults. TS01 selectively targets occlusive clots that cause strokes and spares hemostatic clots (good clots), resulting...